Treatment with treprostinil, a medicine that relaxes blood vessels, led to significant and sustained improvements in children with pulmonary hypertension (PH) caused by different lung conditions, according to a retrospective analysis. Findings from the analysis were detailed in the study, “Treprostinil Is Associated With Early and Sustained Improvement…
News
A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary arterial hypertension (PAH). “This study combined [computer-based genetic sequencing] analyses with experimental validation [in cell and animal models] to identify COL1A1, MYL9, COL1A2, and TPM2 as potential key driver genes…
Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in a rat model of PAH. The scientists detailed the development and testing of the treatment, CPD1, in a study that also shed light on the molecular mechanisms through which the…
Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical role of clinical research. Led by PHA Europe, the annual event seeks to raise awareness and improve the lives of those living with pulmonary hypertension (PH), a condition…
Corvista Health will collaborate with Mayo Clinic to evaluate whether its non-invasive Corvista-PH test can improve the detection, risk stratification, and referral accuracy for people with suspected pulmonary hypertension (PH). “Collaborating with Mayo Clinic represents a defining moment for CorVista and for the advancement of pulmonary hypertension diagnostics,”…
Irregular heart rhythms such as atrial fibrillation, which can make the heart beat too fast, and atrial flutter, which causes the heart to beat out of sync, are relatively common in people with pulmonary arterial hypertension (PAH), a new study in the U.S. suggests. Both types of irregular heart rhythms,…
Babies with bronchopulmonary dysplasia (BPD), a lung disorder that affects premature infants and can lead to pulmonary hypertension (PH), may require medications to help manage PH, but often stop requiring the drugs as they grow into toddlerhood, a study found. “Providers noted a decrease in prescriptions of PH medications…
The activity of a gene called RUNX1 may serve as a biological marker of processes that can lead to right heart failure in pulmonary arterial hypertension (PAH), a study reports. Progressive decline of the right ventricle, the chamber of the heart that pumps blood to the lungs, is a…
Elevated pulmonary vascular resistance (PVR), a measure of how difficult it is for blood to move from the heart to the lungs, was associated with a higher risk of poor outcomes in people with pulmonary hypertension (PH) due to left heart disease, a real-world study in Japan shows. The…
Data from smartphones and wearable devices may help with the early detection of idiopathic pulmonary arterial hypertension (IPAH), a rare lung disease with no known cause, a study suggests. Using up to eight years of data obtained via the My Heart Counts iOS app, device-derived data helped distinguish…
Building on positive data from an earlier study, Allrock Bio has dosed the first patients in a small clinical trial testing ROC-101, its oral treatment candidate for pulmonary hypertension (PH). The open-label Phase 2a ROCSTAR study (NCT07175038) is recruiting patients across the U.S., Canada, and Europe — including…
Children with pulmonary hypertension (PH) engage in fewer and shorter bouts of intense physical activity than their peers, according to a new study that measured data from sensors worn on the wrist. Moreover, kids with more severe PH generally had “worse physical testing,” as well as “a steeper decline…
